The company’s lead internal program expands its in vivo CAR T clinical pipeline for patients with relapsed/refractory B cell malignanciesFirst patient expected to be dosed in Q3 2026 SEATTLE, July 16, 2026 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc., a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) recently cleared its Investigational New Drug (IND) application for UB-VV400, a CD22-directed in vivo CAR T cell therapy candidate for adults with relapsed/refractory B cell malignancies."UB-VV400 is our second VivoVec™ based in vivo CAR…